Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Studies showed that infusion or injection of drugs and fluids results in introduction of microparticles into the bloodstream. These microparticles may cause organ damage and stimulate the immune system thus aggravating the underlying disease. Given that critically ill patients are characteristically suffering from a high disease severity and receive large amounts of fluids and drugs, they may be at particular risk of harm by these microparticles. In-line microfilters have been shown to clear microparticles from intravenous drugs and solutions. The investigators hypothesize that use of in-line microfilters reduce the days with the systemic inflammatory response syndrome in adult critically ill patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Use of in-line microfilters | Experimental |
| |
| Standard therapy without the use of in-line microfilters | No Intervention |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| In-line microfilter (Supor IV Filter; Pall Corporation, Port Washington, New York) | Device | use of in-line microfilters with a pore size of 0,2 mcm and 1,2 mcm (only if parenteral nutrition is administered) at all intravenous accesses |
| Measure | Description | Time Frame |
|---|---|---|
| Number of days in the intensive care unit with the systemic inflammatory response syndrome | participants will be followed for the duration of ICU stay, an expected average of 5 days |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of the systemic inflammatory response syndrome during the intensive care unit stay | participants will be followed for the duration of ICU stay, an expected average of 5 days | |
| Average number of days with the systemic inflammatory response syndrome during the intensive care unit stay |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Martin W Duenser, MD, DESA, EDIC | Department of Anesthesiology, perioperative and intensive care medicine, Salzburg General Hospital and Paracelsus Private Medical University | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Anesthesiology, perioperative and intensive care medicine, Salzburg General Hospital and Paracelsus Private Medical University | Salzburg | State of Salzburg | 5020 | Austria |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26538309 | Derived | Gradwohl-Matis I, Brunauer A, Dankl D, Wirthel E, Meburger I, Bayer A, Mandl M, Dunser MW, Grander W. Influence of in-line microfilters on systemic inflammation in adult critically ill patients: a prospective, randomized, controlled open-label trial. Ann Intensive Care. 2015 Dec;5(1):36. doi: 10.1186/s13613-015-0080-x. Epub 2015 Nov 4. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D016638 | Critical Illness |
| ID | Term |
|---|---|
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| participants will be followed for the duration of ICU stay, an expected average of 5 days |
| Length of stay in the intensive care unit | participants will be followed for the duration of ICU stay, an expected average of 5 days |
| Duration of mechanical ventilation | participants will be followed for the duration of ICU stay, an expected average of 5 days |
| Incidence of acute lung injury and the acute respiratory distress syndrome | participants will be followed for the duration of ICU stay, an expected average of 5 days |
| Maximum C-reactive protein serum concentrations during the intensive care unit stay | participants will be followed for the duration of ICU stay, an expected average of 5 days |
| Maximum leukocyte count during the intensive care unit stay | participants will be followed for the duration of ICU stay, an expected average of 5 days |
| Incidence of nosocomial infections during the intensive care unit stay | participants will be followed for the duration of ICU stay, an expected average of 5 days |
| Incidence of nosocomial candida infections during the intensive care unit stay | participants will be followed for the duration of ICU stay, an expected average of 5 days |
| Incidence of venous thrombosis during the intensive care unit stay | participants will be followed for the duration of ICU stay, an expected average of 5 days |
| Cumulative insulin requirements during the intensive care unit stay | participants will be followed for the duration of ICU stay, an expected average of 5 days |
| Number of days with hypo- or hyperglycemic blood sugar levels | participants will be followed for the duration of ICU stay, an expected average of 5 days |